Article

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers

2024-03-24

Abstract excerpt

<h4>PURPOSE</h4> MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy of MAPK pathway inhibitors (MAPKi) for MAP2K1 mutant tumors is not well defined. We sought to characterize the genomic and clinical landscape of MAP2K1 mutant tumors to ev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 561e3811-d9fb-5618-b972-80cb96e8c67f
DOI: 10.1101/2024.03.23.24304779

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancersDOI 10.1101/2024.03.23.24304779Read

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.Semantic proximity Read

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.Semantic proximity Read

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.Semantic proximity Read

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.Semantic proximity Read

Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors.Semantic proximity Read

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesSemantic proximity Read

Integrative Pan-cancer Analysis of MEK1 Aberrations and the Potential Clinical ImplicationsSemantic proximity Read

Targeting MAPK in Cancer 2.0Semantic proximity Read

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read